Clinical Report: Efficacy Data on Eye Drop for DME Presented at RWC
Overview
The DIAMOND stage 1 trial demonstrated that OCS-01, a topical eye drop for diabetic macular edema (DME), achieved significant improvements in best-corrected visual acuity (BCVA) and reductions in retinal thickness compared to placebo. These results suggest OCS-01 may provide a viable alternative to traditional intravitreal injections.
Background
Diabetic macular edema (DME) is a leading cause of vision loss in the working population, necessitating effective treatment options. Current standard therapies primarily involve intravitreal injections, which can be burdensome for patients. The introduction of a topical treatment like OCS-01 could enhance patient compliance and improve outcomes in managing DME.
Data Highlights
| Endpoint | OCS-01 Group | Placebo Group | P-value |
|---|---|---|---|
| Mean BCVA Improvement at Week 6 | 7.2 EDTRS letters | 3.1 EDTRS letters | 0.007 |
| Mean CST Reduction at Week 6 | 69.1 µm | - | - |
| Mean BCVA Improvement at Week 12 | 7.6 EDTRS letters | 3.7 EDTRS letters | 0.016 |
| Proportion Achieving ≥15-letter Gain at Week 12 | 27.4% | 7.5% | 0.009 |
Key Findings
- OCS-01 showed significant BCVA improvement compared to placebo at week 6 (7.2 vs 3.1 letters, P=0.007).
- Statistically significant reductions in central subfield thickness (CST) were observed, with a 69.1 µm decrease at week 6.
- By week 12, 27.4% of patients on OCS-01 achieved a ≥15-letter gain in BCVA compared to 7.5% in the placebo group (P=0.009).
- Both treatment-naïve and previously treated patients experienced visual and anatomical improvements with OCS-01.
- IOP increases were noted in the OCS-01 group, with 22 cases reported, 11 of which required medication.
Clinical Implications
The findings from the DIAMOND stage 1 trial suggest that OCS-01 could be a promising alternative to intravitreal injections for patients with DME, potentially improving patient adherence to treatment. Clinicians should monitor intraocular pressure in patients receiving OCS-01 due to the observed increases.
Conclusion
OCS-01 demonstrates significant efficacy in improving vision and reducing retinal thickness in DME patients, warranting further investigation in the ongoing phase 3 trials.
References
- Ophthalmology Management, 2025 -- Positive Data Reported for Patients with DME
- Retinal Physician, 2025 -- Initial DIAMOND Results Support OCS-01 Efficacy
- Retinal Physician, 2025 -- Oculis Completes Enrollment in DME Trials
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Faricimab Treat-and-Extend for Diabetic Macular Edema - PubMed
- Retinal Physician, 2025 -- Efficacy Data on Eye Drop for DME Presented at RWC
- Retinal Physician — Initial DIAMOND Results Support OCS-01 Efficacy
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials - PubMed
- Efficacy Data on Eye Drop for DME Presented at RWC | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.